News

Tibotec Pharmaceuticals Seeks European Marketing Authorization For Investigational Once-Daily HIV Treatment TMC278

Gilead Sciences Submits European Marketing Application For Once-Daily Single-Tablet Regimen Of Truvada® And TMC278 For The Treatment Of HIV Infect

AVAC Calls For Speedy Funding Of Critical Microbicide Follow-Up Studies

A Scientific Breakthrough On How HIV Takes Control Of Cell Division

Commitments To Global HIV/AIDS Programs Falter For 'First Time In 15 Years,' UNAIDS Chief Says

Contact Information

Main Office

Office hours are M-F 9:00am - 5:00pm

Phone: (310) 473-5500
Fax: (310) 473-7772
11645 Wilshire Blvd.
Suite 770
Los Angeles, CA 90025

email: info@nnab.org